Company profile for Attralus

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Attralus is a biopharmaceutical company focused on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company’s proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. Attralus is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal...
Attralus is a biopharmaceutical company focused on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company’s proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. Attralus is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
‍329 Oyster Point Blvd Third Floor South San Francisco, CA 94080
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/08/3145979/0/en/Attralus-Presents-New-Data-on-Its-Pan-Amyloid-Diagnostic-Imaging-Candidates-at-ASNC-2025.html

GLOBENEWSWIRE
08 Sep 2025

https://www.globenewswire.com/news-release/2025/04/01/3053148/0/en/Attralus-Presents-New-Data-on-Its-Pan-Amyloid-Diagnostic-Candidates-at-the-2025-American-College-of-Cardiology-ACC-Annual-Scientific-Session.html

GLOBENEWSWIRE
01 Apr 2025

https://www.globenewswire.com/news-release/2025/01/15/3009885/0/en/Attralus-Announces-Enrollment-of-First-Patient-in-Phase-3-Trial-for-the-Pan-Amyloid-Diagnostic-124I-evuzamitide-AT-01-for-Cardiac-Amyloidosis.html

GLOBENEWSWIRE
15 Jan 2025

https://www.globenewswire.com/news-release/2024/11/12/2978891/0/en/Attralus-Therapeutic-AT-02-Receives-Orphan-Drug-Designation-from-the-U-S-FDA-for-the-Treatment-of-ATTR-Amyloidosis.html

GLOBENEWSWIRE
12 Nov 2024

https://www.globenewswire.com/news-release/2024/08/05/2924179/0/en/Attralus-Receives-Breakthrough-Therapy-Designation-for-its-Pan-Amyloid-Diagnostic-PET-Imaging-Candidate-124I-evuzamitide-AT-01-for-Cardiac-Amyloidosis.html

GLOBENEWSWIRE
05 Aug 2024

https://www.globenewswire.com/news-release/2024/07/29/2920154/0/en/Attralus-Receives-European-Medicines-Agency-Committee-for-Orphan-Medicinal-Products-COMP-Positive-Opinions-for-AT-02-for-the-Treatment-of-Both-ATTR-and-AL-Amyloidosis.html

GLOBENEWSWIRE
29 Jul 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty